For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.
"The drug delivery sector has been revolutionized by the application of nanotechnologies. And one of the fastest up-and-coming countries in this sector is Australia.
"Starpharma has landed a few significant co-development and assessment deals with some major firms in recent months as it awaits FDA approval for its VivaGel, dendrimer-based topical cream that can prevent the spread of sexually transmitted diseases, specifically Herpes and HIV.
"VivaGel also has spermicidal qualities that are so compelling, one of Starpharma's recent co-development deals was with Durex, one of the world's top condom manufacturers. Durex is considering replacing the near-ubiquitous Non-oxynol 9 spermicidal coating with VivaGel, which is proving to be safe and more effective than N-9.
"What's more, it purchased Michigan-based Dendritic Nanotechnologies (DNT) last year. DNT is a major manufacturer of dendrimers for laboratory and research use.
"Current customers are chemical giant Sigma Aldrich and a bioscience division of pharma giant Merck, which is using dendrimers in state-of-the-art anti-cancer siRNA research. This siRNA sector is getting very hot and Starpharma will also capitalize on that. The stock trades over the counter as a top tier Y share."